3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Diffuse Intrinsic Pontine Glioma
1
Cut-Off Value
1
Carcinosarcoma
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Breast Cancer Lymphedema
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Interventions
pembrolizumab
44
Gemcitabine
23
enfortumab vedotin
21
Nivolumab
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Fluid Therapy
×
1 year
×
Clear all
No trials found.